MCID: RCT020
MIFTS: 46

Rectum Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Adenocarcinoma

MalaCards integrated aliases for Rectum Adenocarcinoma:

Name: Rectum Adenocarcinoma 12 15
Rectal Adenocarcinoma 12 6 17
Adenocarcinoma of Rectum 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1996
NCIt 49 C9383
UMLS 71 C0149978

Summaries for Rectum Adenocarcinoma

Disease Ontology : 12 A rectum cancer that derives from epithelial cells of glandular origin.

MalaCards based summary : Rectum Adenocarcinoma, also known as rectal adenocarcinoma, is related to mammary paget's disease and anal canal adenocarcinoma. An important gene associated with Rectum Adenocarcinoma is APOLD1 (Apolipoprotein L Domain Containing 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Trioxsalen and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and breast, and related phenotype is neoplasm.

Related Diseases for Rectum Adenocarcinoma

Diseases related to Rectum Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 30.9 KRT7 KRT20 EGFR
2 anal canal adenocarcinoma 30.8 KRT7 CDX2 APOLD1
3 cystadenoma 30.5 KRT7 KRT20 CEACAM5
4 rectum neuroendocrine neoplasm 30.5 KRT7 CDX2
5 appendix adenocarcinoma 30.5 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
6 colon adenocarcinoma 30.4 TP53 MYC MSH6 KRT20 KRAS EGFR
7 exanthem 30.4 KRAS HRAS EGFR
8 squamous cell carcinoma 30.4 TP53 MYC KDM4C HRAS EGFR CEACAM5
9 cystadenocarcinoma 30.4 TP53 KRT7 HRAS CEACAM5
10 papillary adenocarcinoma 30.4 TP53 KRT7 KRAS CEACAM5
11 adenoma 30.3 TP53 MSH6 KRT7 KRAS CDX2
12 penile cancer 30.3 TP53 KRAS HRAS EGFR
13 familial adenomatous polyposis 30.3 TP53 MYC MSH6 KRAS HRAS
14 mucinous adenocarcinoma 30.2 TP53 KRT7 KRT20 KRAS EGFR CEACAM5
15 angiosarcoma 30.2 TP53 MYC KRT7 KRAS
16 large intestine cancer 30.2 MIR143 KRAS KDM4C HRAS
17 ovarian cystadenocarcinoma 30.2 TP53 KRAS HRAS EGFR CEACAM5
18 adenosquamous carcinoma 30.2 TP53 KRT7 KRAS EGFR CEACAM5
19 adenocarcinoma 30.2 TP53 MYC MSH6 KRT7 KRT20 KRAS
20 intrahepatic cholangiocarcinoma 30.2 TP53 KRT7 KRT20 KRAS EGFR CDX2
21 lynch syndrome 30.1 TP53 MSH6 KRAS KDM4C HRAS EGFR
22 tubular adenocarcinoma 30.1 KRT7 KRT20 EGFR CEACAM5 CDX2
23 myeloma, multiple 30.1 TP53 MYC KRAS KDM4C HRAS EGFR
24 in situ carcinoma 30.1 TP53 MYC MIR143 HRAS EGFR
25 renal cell carcinoma, nonpapillary 30.1 TP53 MIR143 KRT7 KRT20 KDM4C HRAS
26 cholangiocarcinoma 30.0 TP53 KRT7 KRT20 KRAS EGFR CEACAM5
27 basal cell carcinoma 30.0 TP53 MIR143 KRT7 KRT20 EGFR CEACAM5
28 cystic teratoma 30.0 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
29 teratoma 30.0 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
30 renal cell carcinoma, papillary, 1 29.9 TP53 MYC KRT7 KDM4C HRAS EGFR
31 signet ring cell adenocarcinoma 29.8 TP53 KRT7 KRT20 KRAS HRAS CEACAM5
32 pancreatic adenocarcinoma 29.8 TP53 MYC KRAS HRAS EGFR CDX2
33 anus cancer 29.8 TP53 KRT7 KRAS HRAS EGFR CEACAM5
34 bladder cancer 29.7 TP53 MYC MIR143 KRT20 KRAS HRAS
35 medulloblastoma 29.7 TP53 MYC MSH6 KDM4C HRAS EGFR
36 rectum cancer 29.6 SCRT1 RAB11B MSH6 MIR143 LEPROTL1 KRT20
37 gastric adenocarcinoma 29.4 TP53 MYC KRT7 KRT20 KRAS HRAS
38 colorectal adenocarcinoma 29.3 TP53 MYC MSH6 KRT7 KRT20 KRAS
39 lung cancer susceptibility 3 29.1 TP53 MYC MIR143 KRT7 KRT20 KRAS
40 rectum mucinous adenocarcinoma 11.3
41 colon leiomyosarcoma 10.7 CEACAM5 APOLD1
42 rectum signet ring adenocarcinoma 10.7 CEACAM5 APOLD1
43 hepatic flexure cancer 10.7 KRAS APOLD1
44 cutaneous mucoepidermoid carcinoma 10.7 KRT7 CEACAM5
45 urachal adenocarcinoma 10.7 KRAS CEACAM5
46 immature teratoma of ovary 10.7 KRAS CEACAM5
47 rectosigmoid junction neoplasm 10.7 CEACAM5 APOLD1
48 mucoepidermoid esophageal carcinoma 10.7 TP53 CEACAM5
49 trachea carcinoma in situ 10.7 KRAS HRAS
50 bladder signet ring cell adenocarcinoma 10.6 KRT7 CDX2

Graphical network of the top 20 diseases related to Rectum Adenocarcinoma:



Diseases related to Rectum Adenocarcinoma

Symptoms & Phenotypes for Rectum Adenocarcinoma

MGI Mouse Phenotypes related to Rectum Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDX2 EGFR HRAS KDM4C KRAS MSH6

Drugs & Therapeutics for Rectum Adenocarcinoma

Drugs for Rectum Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
4
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
5
Promethazine Approved, Investigational Phase 3 60-87-7 4927
6 Anesthetics Phase 3
7 Hematoporphyrin Derivative Phase 2, Phase 3
8 Dihematoporphyrin Ether Phase 2, Phase 3
9 Cola Phase 3
10 Antineoplastic Agents, Immunological Phase 3
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Lenograstim Approved, Investigational Phase 2 135968-09-1
13
Melphalan Approved Phase 2 148-82-3 4053 460612
14
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Gemcitabine Approved Phase 2 95058-81-4 60750
17
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
18
Simvastatin Approved Phase 2 79902-63-9 54454
19
Pembrolizumab Approved Phase 2 1374853-91-4
20
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
21
Metformin Approved Phase 2 657-24-9 14219 4091
22
Pancrelipase Approved, Investigational Phase 2 53608-75-6
23
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
24
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
25 Bryostatin 1 Investigational Phase 2 83314-01-6
26 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
27
Veliparib Investigational Phase 2 912444-00-9 11960529
28 Fluorodeoxyglucose F18 Phase 2
29 Angiogenesis Inhibitors Phase 2
30 Anti-Infective Agents Phase 2
31 Antibodies Phase 2
32 Immunoglobulins Phase 2
33 Antibodies, Monoclonal Phase 2
34 Liver Extracts Phase 2
35 Alkylating Agents Phase 2
36 Folic Acid Antagonists Phase 2
37 Dermatologic Agents Phase 2
38 Cyclosporins Phase 2
39 Antifungal Agents Phase 2
40 Calcineurin Inhibitors Phase 2
41 Endothelial Growth Factors Phase 2
42 Immunoglobulin G Phase 2
43 Mitogens Phase 2
44 Anticholesteremic Agents Phase 2
45 Hypolipidemic Agents Phase 2
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
47 Lipid Regulating Agents Phase 2
48 Antidotes Phase 2
49 Hormones Phase 2
50 Hematinics Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer Unknown status NCT00070005 Phase 3
2 Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
3 A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
4 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
5 A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Completed NCT00145769 Phase 3 Short Course Adjuvent Chemotherapy;Long Course Adjuvant Chemotherapy;Concurrent Chemotherapy
6 GRECCAR 8 : Impact on Survival of the Primary Tumor Resection in Rectal Cancer With Unresectable Synchronous Metastasis a Randomized Multicenter Study Completed NCT02314182 Phase 3 Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
7 Phase II Trial Comparing Two Neoadjuvant Treatments in Patients With Ultra-low Rectal Cancer: High-dose Radiotherapy Versus Radio-chemotherapy Completed NCT00979680 Phase 3
8 Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004. Completed NCT03428529 Phase 2, Phase 3 Capecitabine Oral Product;5Fluorouracil
9 European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma Recruiting NCT02505750 Phase 3 Capecitabine
10 A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11) Recruiting NCT02584985 Phase 3
11 Longterm Outcome of Photodynamic Therapy Compared With Chemotherapy Alone in Patients With Advanced Rectal Cancer Suspended NCT01872104 Phase 2, Phase 3
12 Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma Terminated NCT00207831 Phase 3 Tegafur and Uracil
13 A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum Terminated NCT00077233 Phase 3 cetuximab;5-FU;irinotecan;leucovorin;oxaliplatin
14 Non-Operative Treatment for Rectal Cancer Following Complete Response to Neo-Adjuvant Therapy Unknown status NCT01047969 Phase 2 Adjuvant Chemotherapy
15 Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study Unknown status NCT00557713 Phase 2 bevacizumab
16 Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis Unknown status NCT01674309 Phase 2 FOLFORINOX
17 Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer Unknown status NCT00075556 Phase 2 capecitabine
18 Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy Unknown status NCT00254683 Phase 2
19 Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial Unknown status NCT02022852 Phase 2 Capecitabine;XELOX
20 ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE Completed NCT00847119 Phase 2 capecitabine (Xeloda)
21 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
22 Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma Completed NCT02319304 Phase 2 FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
23 A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer Completed NCT00422864 Phase 2 oxaliplatin;fluorouracil;leucovorin
24 A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00080834 Phase 2 DJ-927
25 Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer. Completed NCT03085992 Phase 2 FOLFOXIRI plus Bevacizumab
26 Phase II Study of Bryostatin 1 in Patients With Metastatic Colo-Rectal Adenocarcinoma Completed NCT00003220 Phase 2 bryostatin 1
27 Frontline Chemotherapy "Reinforced" for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX Completed NCT00557102 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
29 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
30 Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer Completed NCT00321685 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Oxaliplatin
31 A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Rectal Adenocarcinoma Recruiting NCT04165772 Phase 2 TSR-042;capecitabine
32 Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma Recruiting NCT02919878 Phase 2 Gemcitabine;capecitabine
33 Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER Recruiting NCT02268006 Phase 2 Capecitabine
34 Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma Recruiting NCT02688712 Phase 2 LY2157299;Capecitabine;Fluorouracil
35 Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial Recruiting NCT02490709 Phase 2
36 Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia Recruiting NCT03000374 Phase 2 Panitumumab;5Fluorouracil;Oxaliplatin;Leucovorin
37 GI-116: Phase II Study of Organ Preservation in Early Rectal Cancer Patients Recruiting NCT03548961 Phase 2 FOLFOX regimen
38 A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients Active, not recruiting NCT02161822 Phase 2 simvastatin
39 Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma Active, not recruiting NCT03503630 Phase 2 COMPOUND 2055269;mFOLFOX
40 Phase II Randomized Multi-center Trial of Total Neoadjuvant Therapy With and Without CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma Not yet recruiting NCT04130854 Phase 2 Radiation Therapy 5Gy x 5 days
41 A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Suspended NCT02921256 Phase 2 Capecitabine;Fluorouracil;Leucovorin;Leucovorin Calcium;Oxaliplatin;Veliparib
42 Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas. Terminated NCT01619696 Phase 2
43 A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma Terminated NCT00625183 Phase 2 capecitabine;oxaliplatin
44 Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth Terminated NCT01632020 Phase 2 Placebo;Metformin
45 A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum Terminated NCT00580073 Phase 2 FOLFOX4;Cetuximab
46 Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma Terminated NCT00353457 Phase 2 Capecitabine, Oxaliplatin and Cetuximab
47 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
48 A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum Terminated NCT00081224 Phase 2 capecitabine;celecoxib
49 (Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment Withdrawn NCT02287727 Phase 2 Regorafenib
50 A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer Withdrawn NCT00070434 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin;Pyridoxine

Search NIH Clinical Center for Rectum Adenocarcinoma

Genetic Tests for Rectum Adenocarcinoma

Anatomical Context for Rectum Adenocarcinoma

MalaCards organs/tissues related to Rectum Adenocarcinoma:

40
Colon, Lymph Node, Breast, Liver, Thyroid, Lung, Skin

Publications for Rectum Adenocarcinoma

Articles related to Rectum Adenocarcinoma:

(show top 50) (show all 1955)
# Title Authors PMID Year
1
Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response. 61
31726418 2020
2
Risk factors and therapeutic significance of inguinal lymph node metastasis in advanced lower rectal cancer. 61
32009191 2020
3
Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study. 61
31690966 2020
4
Metastatic cutaneous deposits as the initial feature of rectal adenocarcinoma. 61
31888409 2020
5
The usefulness of b value threshold map in the evaluation of rectal adenocarcinoma. 61
31642964 2020
6
Seminal Vesicle Adherent to Rectal Wall Following Neoadjuvant Chemoradiotherapy: A Potential False-Positive Diagnostic Pitfall. 61
32008384 2020
7
Local Recurrence After Transanal Total Mesorectal Excision for Rectal Cancer: A Multicenter Cohort Study. 61
31972648 2020
8
Risk factors for conversion in laparoscopic and robotic rectal cancer surgery. 61
31976558 2020
9
A case of a rectal adenocarcinoma mimicking a neuroendocrine tumor in the background mucosa of amoebic colitis. 61
31907859 2020
10
Case report of periorbital metastasis from rectal cancer. 61
31895780 2020
11
COL1A1 and MZB1 as the hub genes influenced the proliferation, invasion, migration and apoptosis of rectum adenocarcinoma cells by weighted correlation network analysis. 61
31901757 2020
12
Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer. 61
31942672 2020
13
Right Ventricle Metastasis from Carcinoma Rectum: Findings on 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography. 61
31949380 2020
14
Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma. 61
32023246 2020
15
Genetic predisposition to colon and rectal adenocarcinoma is mediated by a super-enhancer polymorphism co-activating CD9 and PLEKHG6. 61
31988071 2020
16
Surveillance Intensity Comparison by Risk for T1NX Locally Excised Rectal Adenocarcinoma: a Cost-Effective Analysis. 61
31724115 2020
17
Impact of Preoperative Care for Rectal Adenocarcinoma on Pathologic Specimen Quality and Postoperative Morbidity: A NSQIP Analysis. 61
31672638 2020
18
Initial Experience With Staging Rectal Adenocarcinoma Using 7T Magnetic Resonance Imaging. 61
31445495 2020
19
Pre-treatment ADC image-based random forest classifier for identifying resistant rectal adenocarcinoma to neoadjuvant chemoradiotherapy. 61
31786652 2020
20
Local versus Radical Excision of Early Distal Rectal Cancers: A National Cancer Database Analysis. 61
31898098 2020
21
Rectal cancer: can T2WI histogram of the primary tumor help predict the existence of lymph node metastasis? 61
31278581 2019
22
Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study. 61
31724079 2019
23
Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study. 61
29984382 2019
24
SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. 61
31847830 2019
25
An Integrated Pan-Cancer Analysis and Structure-Based Virtual Screening of GPR15. 61
31835584 2019
26
The integrative knowledge base for miRNA-mRNA expression in colorectal cancer. 61
31792281 2019
27
[Hypothyroidism caused by apatinib in patient with lung metastasis from rectal adenocarcinoma: a case report]. 61
31874556 2019
28
Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. 61
31866577 2019
29
Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. 61
31842797 2019
30
Superior pathologic and clinical outcomes after minimally invasive rectal cancer resection, compared to open resection. 61
31844971 2019
31
Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer. 61
30353366 2019
32
A Multicenter Matched Comparison of Transanal and Robotic Total Mesorectal Excision for Mid and Low-rectal Adenocarcinoma. 61
29916871 2019
33
[Efficiency analysis on functional protection of nerve plane-oriented laparoscopic total mesorectal excision]. 61
31874530 2019
34
Mucinous adenocarcinoma of the colon and rectum: A genomic analysis. 61
31729037 2019
35
Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinoma. 61
31945621 2019
36
Short-course or long-course radiation therapy as a part of a neoadjuvant regimen for stage II & III rectal adenocarcinoma? 61
31949387 2019
37
Spiny keratoderma: Report of three cases. 61
31860150 2019
38
Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report. 61
31852167 2019
39
Factors Predicting Operative Difficulty of Laparoscopic Total Mesorectal Excision. 61
31567928 2019
40
Lymph node metastasis in rectal cancer: comparison of MDCT and MR imaging for diagnostic accuracy. 61
31583447 2019
41
Identification of lncRNAs Associated with Prognosis of Rectal Cancer by Comprehensive Bioinformatics Analysis Based on TCGA. 61
31710439 2019
42
Comprehensive Analysis of Core Genes and Potential Mechanisms in Rectal Cancer. 61
31211595 2019
43
Mucinous rectal cancer: concepts and imaging challenges. 61
30993392 2019
44
A case report of rectal adenocarcinoma with intrahepatic cholangiocarcinoma of the liver. 61
31581864 2019
45
Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy. 61
31785609 2019
46
Combined Proctectomy and Hepatectomy for Metastatic Rectal Cancer Should be Undertaken with Caution: Results of a National Cohort Study. 61
31201596 2019
47
Definitive Chemoradiation for Rectal Cancer: Is There a Role for Dose Escalation? A National Cancer Database Study. 61
31567930 2019
48
Nondiscogenic Sciatica: What Clinical Examination and Imaging Can Tell Us? 61
31760186 2019
49
Evaluation of Extramural Venous Invasion by Diffusion-Weighted Magnetic Resonance Imaging and Computed Tomography in Rectal Adenocarcinoma. 61
31582328 2019
50
The Role of Adjuvant Chemotherapy in ypT0N0 Rectal Adenocarcinoma. 61
30729373 2019

Variations for Rectum Adenocarcinoma

ClinVar genetic disease variations for Rectum Adenocarcinoma:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.1984C>A (p.Leu662Ile)SNV Uncertain significance 232098 rs756859993 5:112173275-112173275 5:112837578-112837578
2 APC NM_000038.6(APC):c.811A>G (p.Met271Val)SNV Uncertain significance 141061 rs587781464 5:112137057-112137057 5:112801360-112801360
3 APC NM_000038.6(APC):c.6152A>G (p.Lys2051Arg)SNV Uncertain significance 559958 rs1554087256 5:112177443-112177443 5:112841746-112841746
4 APC NM_000038.6(APC):c.3160C>T (p.His1054Tyr)SNV Uncertain significance 559960 rs1195583636 5:112174451-112174451 5:112838754-112838754

Expression for Rectum Adenocarcinoma

Search GEO for disease gene expression data for Rectum Adenocarcinoma.

Pathways for Rectum Adenocarcinoma

Pathways related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 TP53 MYC MSH6 KRAS HRAS EGFR
2 12.77 TP53 MYC MSH6 KRAS HRAS EGFR
3 12.72 TP53 MYC KRAS HRAS EGFR
4
Show member pathways
12.63 TP53 MSH6 KRAS HRAS EGFR
5
Show member pathways
12.62 TP53 MYC KRAS HRAS EGFR CDX2
6
Show member pathways
12.59 TP53 MYC KRAS HRAS EGFR
7
Show member pathways
12.54 TP53 MYC KRAS HRAS EGFR
8
Show member pathways
12.39 TP53 MYC KRAS HRAS EGFR
9 12.34 TP53 MYC MIR143 KRAS HRAS EGFR
10 12.3 TP53 MYC KRAS HRAS
11
Show member pathways
12.17 TP53 MYC KRAS HRAS EGFR
12 12.16 TP53 MYC KRAS HRAS EGFR
13 12.13 TP53 MYC KRAS HRAS
14
Show member pathways
12.1 TP53 MYC KRAS HRAS
15
Show member pathways
12.08 MYC KRAS HRAS EGFR
16 12.05 TP53 MYC MSH6 KRAS EGFR
17
Show member pathways
12 TP53 KRAS HRAS EGFR
18 11.99 TP53 MYC MSH6 KRAS EGFR
19 11.93 TP53 MYC KRAS HRAS
20 11.91 TP53 MYC KRAS HRAS
21 11.79 TP53 MYC MSH6
22 11.78 KRAS HRAS EGFR
23 11.65 TP53 MYC HRAS
24 11.64 TP53 KRAS HRAS
25 11.6 TP53 MYC KRAS HRAS EGFR
26 11.57 KRAS HRAS EGFR
27 11.46 TP53 MYC MSH6
28 11.3 MYC KRAS HRAS EGFR
29 11.27 TP53 MYC EGFR
30 11.22 TP53 MYC KRAS HRAS EGFR
31 11.19 KRAS HRAS EGFR
32 11.19 MYC KRAS HRAS EGFR
33
Show member pathways
11.16 RAB1A KRAS HRAS
34
Show member pathways
11.1 KRAS HRAS EGFR
35 10.86 TP53 MYC KRAS HRAS EGFR

GO Terms for Rectum Adenocarcinoma

Biological processes related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 TP53 MYC KRAS KDM4C HRAS
2 MAPK cascade GO:0000165 9.78 MYC KRAS HRAS EGFR
3 Ras protein signal transduction GO:0007265 9.61 TP53 KRAS HRAS
4 cellular response to drug GO:0035690 9.54 TP53 MYC EGFR
5 positive regulation of epithelial cell proliferation GO:0050679 9.5 MYC HRAS EGFR
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 EGFR
7 positive regulation of MAP kinase activity GO:0043406 9.43 KRAS HRAS EGFR
8 positive regulation of cell proliferation GO:0008284 9.43 MYC KRAS KDM4C HRAS EGFR CDX2
9 response to isolation stress GO:0035900 9.16 KRAS HRAS
10 intrinsic apoptotic signaling pathway GO:0097193 8.8 TP53 MSH6 HRAS

Molecular functions related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GDP binding GO:0019003 8.8 RAB11B KRAS HRAS

Sources for Rectum Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....